After 30 years of speculation about whether the three month shot makes women more likely to contract HIV, we finally have an answer.
The ECHO trial is out: Depo Provera doesn’t lead to HIV
Subscribe for R500/year
Thanks for enjoying the Mail & Guardian, we’re proud of our 36 year history, throughout which we have delivered to readers the most important, unbiased stories in South Africa. Good journalism costs, though, and right from our very first edition we’ve relied on reader subscriptions to protect our independence.
Digital subscribers get access to all of our award-winning journalism, including premium features, as well as exclusive events, newsletters, webinars and the cryptic crossword. Click here to find out how to join them and get a 57% discount in your first year.
WELCOME TO YOUR M&G
If you’re reading this, you clearly have great taste
If you haven’t already, you can subscribe to the Mail & Guardian for less than the cost of a cup of coffee a week, and get more great reads.
Already a subscriber? Sign in here
Advertising
Subscribers only
Advertising
press releases
Loading latest Press Releases…
